61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
CSL Ltd
Closed
Sector
273.52 -0.23
Overview
Share price change
24h
Min
273
Max
275.91
Income | 741M |
|---|---|
Sales | 6.7B |
P/E Sector Avg | 31.988 42.764 |
EPS | 1.831 |
Dividend yield | 1.411 |
Profit margin | 10.983 |
Employees | 30,398 |
EBITDA | 1.7B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +20.79 upside |
Dividend yield Sector Avg | 1.41% 2.30% |
|---|---|
Next Earnings | 11 Feb 2025 |
Next Dividend date | 2 Apr 2025 |
Next Ex Dividend date | 7 Mar 2025 |
Market Cap | -2.4B 133B |
|---|---|
Previous open | 273.75 |
Previous close | 273.52 |
News Sentiment
By Acuity
17%
83%
37 / 474 Industrials
CSL Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
CSL Ltd Forecast
Price Target
By TipRanks
20.79% upside
12 Months Forecast
Average 331.664 AUD 20.79%
High 345 AUD
Low 318 AUD
Based on 9 Wall Street analysts offering 12 month price targets forCSL Ltd - Dist in the last 3 months.
Sentiment
By Acuity
37 / 474
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About CSL Ltd
CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.
